EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Synthesis of the Abiraterone Derivatives 5α‐ and 5β‐Δ 1 ‐Abiraterone and Structural Determination of an Unknown Metabolite in Human Serum Derived from Oral Abiraterone Acetate

Noboru Hayama iD, Shizuyo Horiyama iD, Ryoma Okamoto, Yukina Nishi, Manae Yada, Ryuji Higashida, Jun Haginaka iD, Yoshihide Usami iD

ChemBioChem · 2025

DOI: 10.1002/cbic.202500675 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ChemBioChem, 2025. Verfasst von Noboru Hayama und 7 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan. Hauptthemen laut MEDLINE: Androstenes, Abiraterone Acetate, Antineoplastic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abiraterone (Abi) acetate, an anticancer drug, produces metabolites in the serum of patients with prostate cancer. Three unknown metabolites of Abi are previously discovered and the structures of two of these compounds are determined by comparing their LC‐based retention times with those of synthesized compounds. However, the structure of the third metabolite is not identified. Herein, two new Abi derivatives, 5α‐Δ 1 ‐abiraterone (5α‐D1A) and 5β‐Δ 1 ‐abiraterone (5β‐D1A), with a molecular weight of 348, are successfully synthesized as candidates for the third unknown metabolite. 5β‐D1A is confirmed as this third metabolite based on its retention time in the extracted ion chromatogram. The metabolic pathway may have formed 5β‐D1A rather than 5α‐D1A because of the higher activity of steroid 5β‐reductase compared with that of 5α‐reductase. These findings are expected to lead to the discovery of new metabolic pathways.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AndrostenesAbiraterone AcetateAntineoplastic AgentsHumansAdministration, OralMaleProstatic NeoplasmsMolecular Structure

Stichwörter der Autor:innen

abirateronemetaboliteolefinationprostate cancersteroid

Substanzen

AndrostenesAbiraterone AcetateabirateroneAntineoplastic Agents

Autor:innen und Institutionen

  • Faculty of Pharmacy, Osaka Medical and Pharmaceutical University, 4-20-1 Nasahara, Takatsuki, Osaka, 569-1094, Japan.
  • School of Pharmacy and Pharmaceutical Sciences, Mukogawa Women's University, 11-68 Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan.
  • Institute for Biosciences, Mukogawa Women's University, 11-68 Koshien Kyuban-cho, Nishinomiya, 663-8179, Japan.

ORCID-Profile: Noboru Hayama, Shizuyo Horiyama, Jun Haginaka, Yoshihide Usami

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Hayama, N., Horiyama, S., Okamoto, R., Nishi, Y., Yada, M., Higashida, R., Haginaka, J., & Usami, Y. (2025). Synthesis of the Abiraterone Derivatives 5α‐ and 5β‐Δ 1 ‐Abiraterone and Structural Determination of an Unknown Metabolite in Human Serum Derived from Oral Abiraterone Acetate. ChemBioChem. https://doi.org/10.1002/cbic.202500675

Vancouver

Hayama N, Horiyama S, Okamoto R, Nishi Y, Yada M, Higashida R, et al. Synthesis of the Abiraterone Derivatives 5α‐ and 5β‐Δ 1 ‐Abiraterone and Structural Determination of an Unknown Metabolite in Human Serum Derived from Oral Abiraterone Acetate. ChemBioChem. 2025. doi:10.1002/cbic.202500675

BibTeX
@article{Hayama2025,
  author = {Hayama, Noboru and Horiyama, Shizuyo and Okamoto, Ryoma and Nishi, Yukina and Yada, Manae and Higashida, Ryuji and Haginaka, Jun and Usami, Yoshihide},
  title = {Synthesis of the Abiraterone Derivatives 5α‐ and 5β‐Δ 1 ‐Abiraterone and Structural Determination of an Unknown Metabolite in Human Serum Derived from Oral Abiraterone Acetate},
  journal = {ChemBioChem},
  year = {2025},
  doi = {10.1002/cbic.202500675}
}
Kostenlos starten →